PURPOSE: To assess the safety of administering bortezomib to patients undergoing a radical prostatectomy, to assess pathologic changes induced by bortezomib in prostate cancer specimen, and to verify alterations by the drug in proteasome protein targets. EXPERIMENTAL DESIGN: Bortezomib is a proteasome inhibitor that has shown activity in vitro and in vivo in prostate cancer. We performed a neoadjuvant clinical trial of bortezomib in men with prostate cancer at high risk of recurrence. The primary endpoints were to evaluate safety and biological activity. RESULTS: Bortezomib is generally safe in the preoperative setting. Antitumor activity was manifested by tumor cytopathic effect, drops in serum prostate-specific antigen in some patients, and increases in tumor apoptosis. This was associated with cytoplasmic entrapment of nuclear factor-kappaB. We found an unexpected increase in proliferation in treated tissues and in vitro. Bortezomib also increased SRC-3 levels and phosphorylated Akt, both in vitro and in treated prostate cancer tissues. Knockdown of SRC-3 blocked the increase in activated Akt in vitro. Combined treatment with bortezomib and the Akt inhibitor perifosine was more effective than either agent alone in vitro. CONCLUSION: These data suggest that combined therapies targeting the proteasome and the Akt pathway may have increased efficacy.
PURPOSE: To assess the safety of administering bortezomib to patients undergoing a radical prostatectomy, to assess pathologic changes induced by bortezomib in prostate cancer specimen, and to verify alterations by the drug in proteasome protein targets. EXPERIMENTAL DESIGN:Bortezomib is a proteasome inhibitor that has shown activity in vitro and in vivo in prostate cancer. We performed a neoadjuvant clinical trial of bortezomib in men with prostate cancer at high risk of recurrence. The primary endpoints were to evaluate safety and biological activity. RESULTS:Bortezomib is generally safe in the preoperative setting. Antitumor activity was manifested by tumor cytopathic effect, drops in serum prostate-specific antigen in some patients, and increases in tumor apoptosis. This was associated with cytoplasmic entrapment of nuclear factor-kappaB. We found an unexpected increase in proliferation in treated tissues and in vitro. Bortezomib also increased SRC-3 levels and phosphorylated Akt, both in vitro and in treated prostate cancer tissues. Knockdown of SRC-3 blocked the increase in activated Akt in vitro. Combined treatment with bortezomib and the Akt inhibitor perifosine was more effective than either agent alone in vitro. CONCLUSION: These data suggest that combined therapies targeting the proteasome and the Akt pathway may have increased efficacy.
Authors: Xiaotao Li; David M Lonard; Sung Yun Jung; Anna Malovannaya; Qin Feng; Jun Qin; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley Journal: Cell Date: 2006-01-27 Impact factor: 41.582
Authors: Bridget N Fahy; Michael G Schlieman; Melinda M Mortenson; Subbulakshmi Virudachalam; Richard J Bold Journal: Cancer Chemother Pharmacol Date: 2005-03-25 Impact factor: 3.333
Authors: Fritz Offner; Olga Samoilova; Evgenii Osmanov; Hyeon-Seok Eom; Max S Topp; João Raposo; Viacheslav Pavlov; Deborah Ricci; Shalini Chaturvedi; Eugene Zhu; Helgi van de Velde; Christopher Enny; Aleksandra Rizo; Burhan Ferhanoglu Journal: Blood Date: 2015-07-31 Impact factor: 22.113
Authors: S G Zhao; W C Jackson; V Kothari; M J Schipper; N Erho; J R Evans; C Speers; D A Hamstra; Y S Niknafs; P L Nguyen; E M Schaeffer; A E Ross; R B Den; E A Klein; R B Jenkins; E Davicioni; F Y Feng Journal: Prostate Cancer Prostatic Dis Date: 2015-05-19 Impact factor: 5.554